

A7
J825
7495
66
1156

~~Copyright~~

JANUARY 1977

Volume 66 Number 1

Coden: JPMSAE 66(1) 1-148 (1977)

JA 2477

**PHARMACY LIBRARY
SCHOOL OF PHARMACY**

JOURNAL OF PHARMACEUTICAL SCIENCES



A publication of the American Pharmaceutical Association

Journal of Pharmaceutical Sciences



JANUARY 1977

VOLUME 66 NUMBER 1

MARY H. FERGUSON
Editor

L. LUAN CORRIGAN
Assistant Editor

SHELLY ELLIOTT
Production Editor

JANET D. SHOFF
Copy Editor

EDWARD G. FELDMANN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

LELAND J. ARNEY
Director of Publications

EDITORIAL ADVISORY BOARD

| | |
|----------------------|-----------------------|
| JOHN AUTIAN | HARRY B. KOSTENBAUDER |
| NORMAN R. FARNSWORTH | HERBERT A. LIEBERMAN |
| WILLIAM O. FOYE | DAVID E. MANN, JR. |
| WILLIAM J. JUSKO | GERALD J. PAPARIELLO |

The *Journal of Pharmaceutical Sciences* is published monthly by the American Pharmaceutical Association at 2215 Constitution Ave., N.W., Washington, DC 20037. Second-class postage paid at Washington, D.C., and at additional mailing office.

All expressions of opinion and statements of supposed fact appearing in articles or editorials carried in this journal are published on the authority of the writer over whose name they appear and are not to be regarded as necessarily expressing the policies or views of the American Pharmaceutical Association.

Offices—Editorial, Advertising, and Subscription Offices: 2215 Constitution Ave., N.W., Washington, DC 20037. Printing Offices: 20th & Northampton Streets, Easton, PA 18042.

Annual Subscriptions—United States and foreign, industrial and government institutions \$50, educational institutions \$50, individuals *for personal use only* \$30; single copies \$5. All foreign subscriptions add \$5 for postage. Subscription rates are subject to change without notice. Members of the American Pharmaceutical Association may elect to receive the *Journal of Pharmaceutical Sciences* as a part of their annual \$60 (foreign \$65) APHA membership dues.

Claims—Missing numbers will not be supplied if dues or subscriptions are in arrears for more than 60 days or if claims are received more than 60 days after the date of the issue, or if loss was due to failure to give notice of change of address. The Association cannot accept responsibility for foreign delivery when its records indicate shipment has been made.

Change of Address—Members and subscribers should notify at once both the Post Office and the American Pharmaceutical Association, 2215 Constitution Ave., N.W., Washington, DC 20037, of any change of address.

© Copyright 1977, American Pharmaceutical Association, 2215 Constitution Ave., N.W., Washington, DC 20037; all rights reserved.

THE "DUMB COPS" IMAGE

One day this past fall we were going through the daily Washington ritual of reviewing the current issue of the *Federal Register*—which is the principal means of keeping track of what is happening in the executive branch of government—when we spotted reference to a Presidential Proclamation which caught our eye. Specifically, the entry pertained to the designation of "Drug Abuse Prevention Week" and the thought struck us that this annual effort to promote means to control the problems of drug abuse was a bit later than usual this year.

Upon turning to the Proclamation in that issue of the *Federal Register*, the explanation became immediately clear. Although the Proclamation was signed by President Ford on October 18 and printed rather promptly in the *Federal Register* dated October 20, nevertheless, the week being so designated was indicated as beginning October 17. Normally, such Proclamations appear at least two weeks or so before the pertinent date and certainly not after the observance is to begin.

Those familiar with the operation of executive agencies will recognize that the tardiness here does not lie with the President, or the White House staff, or the *Federal Register* but, rather, with the particular agency having primary responsibility for the subject area. In this instance, we suspect that the fault lies with the Drug Enforcement Administration of the Department of Justice.

Whether or not DEA was responsible for this small flub, there is no question that the agency has been clearly at fault for a long string of other foul-ups and errors which, *in toto*, project the image of an inefficient, bungling agency.

When DEA was originally established some half-dozen years or so ago, a strong argument was made that responsibility for drug control involved scientific, medical, and other technical knowledge, which argues rather strongly that the agency should be placed within the U.S. Department of Health, Education, and Welfare rather than the Department of Justice. Others, however, argued vocally that drug abuse control basically is a regulatory and enforcement activity and, as such, the agency more properly should be made part of the Department of Justice where other federal investigative and police activities are primarily centralized.

In recent months, we have seen repeated instances where official notices, proposals, or finalized regulations issuing from DEA and published in the *Federal Register* have used terminology and nomenclature to describe the drugs involved which have been confusing, inconsistent, or otherwise inaccurate. In an effort to correct this problem, at our suggestion, the office of the United States Adopted Names (USAN) Council specifically communicated with the DEA and offered assistance in this regard. Not only did the DEA fail to take advantage of this offer but, in fact, actually repeated on at least two later dates the very error cited by the USAN Council office as an example of incorrect drug nomenclature being employed by the agency.

There are many dedicated and well-qualified professionals who serve in the DEA. Undoubtedly, the bureaucratic bungling of the agency such as that described above and which projects a "dumb cop" image is highly embarrassing to those professional staff members. What is particularly unfortunate, however, is that this problem is so unnecessary. It could be readily corrected if those responsible for determining general agency policy and direction were just a bit more sensitive to the need to exercise reasonable sophistication and care in the scientific and medically related aspects of their field of responsibility.



REVIEW ARTICLE

Pharmaceutical Salts

STEPHEN M. BERGE *†, LYLE D. BIGHLEY *, and
DONALD C. MONKHOUSE *

Keyphrases □ Pharmaceutical salts—general pharmacy, physicochemical properties, bioavailability, pharmaceutical properties, toxicology, review □ Salts, pharmaceutical—general pharmacy, physicochemical properties, bioavailability, pharmaceutical properties, toxicology, review □ Physicochemical properties—dissolution, solubility, stability, and organoleptic properties of pharmaceutical salts, review □ Bioavailability—formulation effects, absorption alteration and pharmacokinetics of pharmaceutical salts, review □ Toxicology—pharmaceutical salts, review

CONTENTS

| | |
|---|----|
| <i>Potentially Useful Salts</i> | 2 |
| <i>Physicochemical Studies</i> | 4 |
| Dissolution Rate | 5 |
| Solubility | 7 |
| Organoleptic Properties | 8 |
| Stability | 9 |
| Miscellaneous Properties | 10 |
| <i>Bioavailability</i> | 10 |
| Formulation Effects | 11 |
| Absorption Alteration | 11 |
| Pharmacokinetics | 13 |
| <i>General Pharmacy</i> | 14 |
| Pharmacological Effect | 14 |
| Dialysis | 14 |
| Miscellaneous | 14 |
| <i>Toxicological Considerations</i> | 15 |
| Toxicity of Salt Ion | 15 |
| Toxicity of Salt Form | 15 |
| <i>Conclusions</i> | 16 |
| <i>References</i> | 16 |

The chemical, biological, physical, and economic characteristics of medicinal agents can be manipulated and, hence, often optimized by conversion to a salt form. Choosing the appropriate salt, however, can be a very difficult task, since each salt imparts unique properties to the parent compound.

Salt-forming agents are often chosen empirically. Of the many salts synthesized, the preferred form is selected by pharmaceutical chemists primarily on a practical basis: cost of raw materials, ease of crystallization, and percent yield. Other basic considerations include stability, hygroscopicity, and flowability of the resulting bulk drug. Unfortunately, there is no reliable way of predicting the influence of a particular salt species on the behavior of the parent compound. Furthermore, even after many salts of the same basic agent have been prepared, no efficient screening techniques exist to facilitate selection of the salt most likely to exhibit the desired pharmacokinetic, solubility, and formulation profiles.

Some decision-making models have, however, been developed to help predict salt performance. For example, Walkling and Appino (1) described two techniques, "decision analysis" and "potential problem analysis," and applied them to the selection of the most suitable derivative of an organic acid for development as a tablet. The derivatives considered were the free acid and the potassium, sodium, and calcium salts. Both techniques are based on the chemical, physical, and biological properties of these specific derivatives and offer a promising avenue for developing optimal salt forms.

Information on salts is widely dispersed throughout the pharmaceutical literature, much of which addresses the use of salt formation to prolong the release of the active component, thereby eliminating various undesirable drug properties (2-6). This review surveys literature of the last 25 years, emphasizing comparisons between the properties of different salt forms of the same compound. Included also is a discussion of potentially useful salt forms. Our purpose is twofold: to present an overview of the many different salts from which new drug candidates can be chosen and

Table I—FDA-Approved Commercially Marketed Salts

| Anion | Percent ^a | *Anion | Percent ^a |
|-----------------------------------|----------------------|--------------------------|----------------------|
| Acetate | 1.26 | Iodide | 2.02 |
| Benzenesulfonate | 0.25 | Isethionate ⁱ | 0.88 |
| Benzoate | 0.51 | Lactate | 0.76 |
| Bicarbonate | 0.13 | Lactobionate | 0.13 |
| Bitartrate | 0.63 | Malate | 0.13 |
| Bromide | 4.68 | Maleate | 3.03 |
| Calcium edetate | 0.25 | Mandelate | 0.38 |
| Camsylate ^b | 0.25 | Mesylate | 2.02 |
| Carbonate | 0.38 | Methylbromide | 0.76 |
| Chloride | 4.17 | Methylnitrate | 0.38 |
| Citrate | 3.03 | Methylsulfate | 0.88 |
| Dihydrochloride | 0.51 | Mucate | 0.13 |
| Edetate | 0.25 | Napsylate | 0.25 |
| Edisylate ^c | 0.38 | Nitrate | 0.64 |
| Estolate ^d | 0.13 | Pamoate (Embonate) | 1.01 |
| Esylate ^e | 0.13 | Pantothenate | 0.25 |
| Fumarate | 0.25 | Phosphate/diphosphate | 3.16 |
| Gluceptate ^f | 0.18 | Polygalacturonate | 0.13 |
| Gluconate | 0.51 | Salicylate | 0.88 |
| Glutamate | 0.25 | Stearate | 0.25 |
| Glycollylsarbanilate ^g | 0.13 | Subacetate | 0.38 |
| Hexylresorcinate | 0.13 | Succinate | 0.38 |
| Hydrabamine ^h | 0.25 | Sulfate | 7.46 |
| Hydrobromide | 1.90 | Tannate | 0.88 |
| Hydrochloride | 42.98 | Tartrate | 3.54 |
| Hydroxynaphthoate | 0.25 | Teoate ^j | 0.13 |
| | | Triethiodide | 0.13 |
| Cation | Percent ^a | Cation | Percent ^a |
| Organic: | | Metallic: | |
| Benzathine ^k | 0.66 | Aluminum | 0.66 |
| Chlorprocaine | 0.33 | Calcium | 10.49 |
| Choline | 0.33 | Lithium | 1.64 |
| Diethanolamine | 0.98 | Magnesium | 1.31 |
| Ethylenediamine | 0.66 | Potassium | 10.82 |
| Meglumine ^l | 2.29 | Sodium | 61.97 |
| Procaine | 0.66 | Zinc | 2.95 |

^a Percent is based on total number of anionic or cationic salts in use through 1974. ^b Camphorsulfonate. ^c 1,2-Ethanedisulfonate. ^d Lauryl sulfate. ^e Ethanesulfonate. ^f Glucoheptonate. ^g *p*-Glycolamidophenylarsonate. ^h *N,N'*-Di(dehydroabietyl)ethylenediamine. ⁱ 2-Hydroxyethanesulfonate. ^j 8-Chlorotheophyllinate. ^k *N,N'*-Dibenzylethylenediamine. ^l *N*-Methylglucamine.

to assemble data that will provide, for the student and practitioner alike, a rational basis for selecting a suitable salt form.

POTENTIALLY USEFUL SALTS

Salt formation is an acid-base reaction involving either a proton-transfer or neutralization reaction and is therefore controlled by factors influencing such reactions. Theoretically, every compound that exhibits acid or base characteristics can participate in salt formation. Particularly important is the relative strength of the acid or base—the acidity and basicity constants of the chemical species involved. These factors determine whether or not formation occurs and are a measure of the stability of the resulting salt.

The number of salt forms available to a chemist is large; surveys of patent literature show numerous new salts being synthesized annually. Various salts of the same compound often behave quite differently because of the physical, chemical, and thermodynamic properties they impart to the parent compound. For example, a salt's hydrophobicity and high crystal lattice energy can affect dissolution rate and, hence, bioavailability. Ideally, it would be desirable if one could predict how a pharmaceutical agent's properties would be affected by salt formation.

Tables I and II list all salts that were commercially marketed through 1974. The list was compiled from all agents listed in "Martindale's The Extra Pharmacopoeia"

26th ed. (7). Table I categorizes all salt forms approved by the Food and Drug Administration (FDA), while Table II lists those not approved by the FDA but in use in other countries. (Only salts of organic compounds are considered because most drugs are organic substances.) The relative frequency with which each salt type has been used is calculated as a percentage, based on the total number of anionic or cationic salts in use through 1974. Because of simple availability and physiological reasons, the monoprotic hydrochlorides have been by far the most frequent choice of the available anionic salt-forming radicals, outnumbering the sulfates nearly six to one. For similar reasons, sodium has been the most predominant cation.

Knowledge that one salt form imparts greater water solubility, is less toxic, or slows dissolution rate would greatly benefit chemists and formulators. In some cases, such generalizations can be made. Miller and Heller (8) discussed some properties associated with specific classes of salt forms. They stated that, in general, salt combinations with monocarboxylic acids are insoluble in water and lend themselves to repository preparations, while those of dicarboxylic acids confer water solubility if one carboxylic group is left free. Pamoic acid, an aromatic dicarboxylic acid, is an exception since it is used as a means of obtaining prolonged action by forming slightly soluble salts with certain basic drugs. Saias *et al.* (9) reviewed the use of this salt form in preparing sustained-release preparations.

Table II—Non-FDA-Approved Commercially Marketed Salts

| Anion | Percent ^a |
|---------------------------|----------------------|
| Adipate | 0.13 |
| Alginate | 0.13 |
| Aminosalicylate | 0.25 |
| Anhydromethylenecitrate | 0.13 |
| Arecoline | 0.13 |
| Aspartate | 0.25 |
| Bisulfate | 0.25 |
| Butylbromide | 0.13 |
| Camphorate | 0.13 |
| Digluconate | 0.13 |
| Dihydrobromide | 0.13 |
| Disuccinate | 0.13 |
| Glycerophosphate | 0.88 |
| Hemisulfate | 0.13 |
| Hydrofluoride | 0.13 |
| Hydroiodide | 0.25 |
| Methylenebis(salicylate) | 0.13 |
| Napadisylate ^b | 0.13 |
| Oxalate | 0.25 |
| Pectinate | 0.13 |
| Persulfate | 0.13 |
| Phenylethylbarbiturate | 0.13 |
| Picrate | 0.13 |
| Propionate | 0.13 |
| Thiocyanate | 0.13 |
| Tosylate | 0.13 |
| Undecanoate | 0.13 |
| Cation | Percent ^a |
| Organic: | |
| Benethamine ^c | 0.33 |
| Clemizole ^d | 0.33 |
| Diethylamine | 0.33 |
| Piperazine | 0.98 |
| Tromethamine ^e | 0.33 |
| Metallic: | |
| Barium | 0.33 |
| Bismuth | 0.98 |

^a Percent is based on total number of anionic and cationic salts in use through 1974. ^b 1,5-Naphthalenedisulfonate. ^c *N*-Benzyphenethylamine. ^d 1-*p*-Chlorobenzyl-2-pyrrolidin-1'-ylmethylbenzimidazole. ^e Tris(hydroxymethyl)aminomethane.

using pamoic acid resulted in the formation of a delayed-action preparation. Numerous studies using pamoate salts are dispersed throughout the literature (11–15).

Alginic acid also has been used to prepare long-acting pharmaceuticals. Streptomycin alginate was prepared (16) and shown to be effective in sustained-release preparations. A striking example of a long-acting alginate salt is that of pilocarpine. When dispersed in sterile water and dried to a solid gel, this compound was found useful in the preparation of long-acting ophthalmic dosage forms (17). While liquid preparations of the alginate and hydrochloride salts possess similar miotic activity, studies showed that solid pilocarpine alginate flakes constricted pupil size more effectively and increased the duration of miosis significantly when compared with the liquid preparations. Solid dose pilocarpine may be more uniformly available, because it diffuses more slowly through the gel matrix which holds the drug in reserve. In contrast, drops of the commonly employed solution dosage form release the dose immediately to the conjunctival fluid.

Málek *et al.* (18) devised a unique way of prolonging action through salt formation; they showed that the distribution of several antibiotics could be markedly altered by merely preparing macromolecular salts. Since macromolecules and colloidal particles have an affinity for the

streptothrycin were combined with high molecular weight compounds such as polyacrylic acids, sulfonic or phosphorylated polysaccharides, and polyuronic derivatives. Parenteral administration of these compounds produced low blood levels of the antibiotic for long periods, while lymph levels were high. (In comparison, streptomycin sulfate gave high blood levels but low lymph levels.) This alteration in distribution caused the streptomycin to prolong its passage through the body, since lymphatic circulation is quite slow.

The appropriate choice of a salt form has been found to reduce toxicity. It can be rationalized that any compound associated with the normal metabolism of food and drink must be essentially nontoxic. The approach of choosing organic radicals that are readily excreted or metabolized opened up a new class of substances from which to select a salt form. For example, certain salts of the strong base choline have proven to be considerably less toxic than their parent compound. The preparation and properties of choline salts of a series of theophylline derivatives were reported (19), and it was shown that choline theophyllinate possessed a greater LD₅₀ than theophylline or its other salts (20). It was postulated that this agent would be less irritating to the GI tract than aminophylline, because "its basic constituent, choline, is an almost completely nontoxic substance of actual importance to the physiologic economy." This evidence led to the preparation of choline salicylate (21) as an attempt to reduce the GI disturbances associated with salicylate administration. Clinical studies indicated that choline salicylate elicited a lower incidence of GI distress, was tolerated in higher doses, and was of greater benefit to the patient than was acetylsalicylic acid (aspirin).

Amino acids and acid vitamins also have been used as salt-forming agents. Based on the evidence that coadministration of amino acids with aminoglycoside antibiotics reduced their toxicity, a series of amino acid salts of dihydrostreptomycin was prepared (22). In all but one case, the acute toxicities of these salts were lower than the toxicity of the sulfate. The ascorbate and pantothenate also were synthesized and shown to be less toxic than the sulfate. Of the salts prepared, the ascorbate had the highest LD₅₀.

The vitamins most commonly used for forming salts exhibiting reduced toxicity are ascorbic and pantothenic acids. Keller *et al.* (23) were the first to use pantothenic acid as a means of "detoxifying" the basic streptomyces antibiotics. Parenteral administration of the pantothenates of streptomycin and dihydrostreptomycin had a significantly reduced incidence of acute neurotoxicity in cats as compared with the sulfates. Subsequent studies (24–28) supported this finding and showed that the pantothenates of neomycin and viomycin also are less toxic. The ascorbate of oleandomycin was synthesized and its pharmacological properties were reported (29). Upon intramuscular injection in rats, it produced less irritation than the phosphate.

p-Acetamidobenzoic acid, an innocuous metabolite of folic acid present in normal blood and urine, has been used in preparing salts. In particular, it yields stable salts with amines that otherwise tend to form hygroscopic products with conventional acid components (30).

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.